S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS

Kim Linton

Research output: Contribution to journal › Meeting Abstract › peer-review

1 Downloads (Pure)
Original languageEnglish
JournalHemaSphere
Publication statusPublished - 2023
EventEHA2023 Hybrid Congress - Frankfurt, Germany
Duration: 8 Jun 2023 → 15 Jun 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  • SDG 3 - Good Health and Well-being

Access to Document

  • S234Final published version, 127 KB

    Cite this